Health Sciences Acquisitions Corporation

Health Sciences Acquisitions Corporation was a healthcare-focused special purpose acquisition company that filed its S-1 with the SEC on April 16, 2019, targeting the life sciences and biopharmaceutical sector. The SPAC completed its business combination with Immunovant, Inc., a clinical-stage immunology company developing treatments for autoimmune diseases, with the combined entity now trading on Nasdaq under the ticker IMVT. The transaction, which closed in late 2019, effectively transitioned Health Sciences Acquisitions Corporation from a blank-check vehicle into an operating biopharmaceutical company. For full filing history, sponsor details, deal terms, and post-merger performance data on IMVT and thousands of other SPAC transactions, sign up for SpacDesk at spacdesk.com.